On this page
- What the literature contains
- Cognitive decline is a symptom, not a diagnosis
- Why this is such a reliable selling point
- The distinction that matters clinically
- What has evidence for cognition
- Why the measurement problem is fatal here
- What is being sold instead
- If you want to be assessed anyway
- Questions worth asking
- Frequently asked questions
- Requesting a medical evaluation
“Brain fog”, declining memory and slower thinking are among the most common reasons people enquire about regenerative treatment, and among the least studied. Stem cell therapy for cognitive decline has no trial that set out to treat it: where cognition has been measured at all, it has been a secondary measure in trials of something else.
What the literature contains
Cognition has been examined within multiple sclerosis research — Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial.
A related study tracked blood markers of nerve injury alongside cognitive change in the same population — Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells.
Both are in people with multiple sclerosis, where cognitive impairment arises from a specific disease process. Neither studied cognitive decline as a condition in its own right, and the word “preliminary” in the first title is the authors’ own.
Cognitive decline is a symptom, not a diagnosis
Slower thinking and poorer memory are produced by a long list of conditions, and the useful first step is finding out which one applies.
Depression is the most commonly missed cause and is treatable. So are thyroid disease, vitamin B12 deficiency, obstructive sleep apnoea, chronic alcohol use, and the side effects of several extremely common medications.
Hearing loss is strongly associated with cognitive decline and is correctable. Untreated, it also makes cognitive testing unreliable, so it confounds both the problem and its measurement.
None of those is addressed by an infusion, and all of them should be excluded before anything experimental is contemplated.
Why this is such a reliable selling point
Almost everyone over forty notices some change in memory and concentration, and almost everyone worries about it. That makes the market effectively universal.
The symptom fluctuates enormously with sleep, stress, workload and mood. Someone who takes a trip, rests, and receives attention will usually feel sharper afterwards.
There is also no agreed measurement. Without a defined scale and a control group, “I feel clearer” is unfalsifiable, which is precisely what makes it saleable.
The distinction that matters clinically
Subjective cognitive complaint means you notice a change and formal testing is normal. Mild cognitive impairment means testing shows a measurable deficit that does not yet affect daily function. Dementia means function is affected.
These carry very different outlooks. Many people with subjective complaints never progress; a proportion of those with mild cognitive impairment do.
Knowing which applies changes what should be done, and no treatment decision is sensible before that assessment. Alzheimer’s disease and dementia covers the far end of that spectrum.
What has evidence for cognition
Treating the conditions listed above, where present.
Physical exercise has the most consistent evidence of anything studied for cognitive ageing, across multiple randomised trials.
Blood pressure control in midlife, hearing correction, treating sleep apnoea, and reducing alcohol all have supporting evidence. None of them is exciting, and collectively they outperform anything on offer in this sector.
Social and cognitive engagement is associated with better outcomes, though the direction of that relationship is harder to establish — people who are declining withdraw, as well as the reverse.
What none of these do is produce a dramatic change in a fortnight, which is part of why they compete poorly against something sold as a single decisive intervention.
Why the measurement problem is fatal here
Every trial that measures cognition uses a defined battery of tests with published norms adjusted for age and education, administered by someone blinded to what the patient received.
That apparatus exists because cognitive testing without it is unreliable. Scores improve on repeat testing simply through familiarity with the tasks — the practice effect — and that improvement is large enough to swamp the effect sizes anyone is claiming.
A clinic that tests you before treatment and again afterwards, unblinded, with no control group, will reliably record an improvement. It would record one if the infusion contained saline.
This is not a reason to avoid testing. It is a reason to be clear about what a before-and-after comparison can and cannot establish.
What is being sold instead
Intravenous infusions, frequently packaged with vitamin drips, hyperbaric oxygen or exosome products, and presented under headings like brain optimisation or neuro-regeneration.
Exosome preparations in particular are marketed heavily for cognition and are graded lowest on this site for a reason — exosome therapy.
The packaging varies. The absence of a controlled trial targeting cognitive decline is constant.
If you want to be assessed anyway
A proper cognitive assessment is worth having in its own right, and it does not require travelling abroad.
It establishes a baseline, which is the only thing that makes later comparison meaningful. Without one, nobody can say whether anything changed.
The patient journey sets out what a records review involves here, including the likelihood that the honest answer is that there is nothing worth treating this way.
An assessment also catches the cases where something else is going on. A proportion of people referred for memory problems turn out to have depression, a sleep disorder or a medication effect, and finding that is worth more than any treatment discussed here.
Questions worth asking
- Have reversible causes been excluded — thyroid, B12, sleep apnoea, depression, medication, hearing?
- Is this subjective complaint, mild cognitive impairment, or dementia?
- Which controlled trial targeted cognitive decline itself?
- What baseline testing would be done, and what would be repeated afterwards?
What the evidence levels mean explains why this page is graded as it is.
Frequently asked questions
Is there a trial for brain fog?
No. Cognition has been measured as a secondary endpoint in multiple sclerosis trials, and no controlled trial has targeted cognitive decline itself.
Why do people report feeling sharper?
Cognition fluctuates with sleep, stress and mood. A rest, a trip and attention produce that feeling reliably, with or without treatment.
What should I do first?
Exclude reversible causes: thyroid, B12, sleep apnoea, depression, medication side effects and hearing loss. All are common and all are treatable.
Does exercise really compare?
It has the most consistent randomised evidence of anything studied for cognitive ageing, which is more than can be said for any infusion.
Are exosomes better for the brain?
They are marketed heavily for cognition and have less evidence than cells, not more.
Is it worth getting tested?
Yes, and it does not require travelling. A baseline is the only thing that makes any later comparison meaningful.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.